The current drug regulatory system is outdated and relies primarily on a process of premarketing evaluation, followed by periodic reviews of reported adverse events.
While long-term medicine use for chronic conditions is now commonplace, current drug evaluation systems do not incorporate the comprehensive evidence accruing over time in clinical practice. Good quality, routinely collected data on medicines use are now available in some countries.
Consistent with international opinion, we propose an expanded and integrated system of medicines regulation for Australia, based on a surveillance system that improves safety monitoring by complementing existing systems, making best use of routinely collected data, and leveraging the power of information technology.
Australia is well placed to pilot such a model system.
- 1. Baciu AS, Stratton K, Burke SP, editors; Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press, 2006. http://www.nap.edu/catalog/11750.html (accessed Jan 2007).
- 2. Britton A, McKee M, Black N, et al. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998; 2: i-iv and 1-124.
- 3. Ray WA, Stein CM. Reform of drug regulation — beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201.
- 4. Moseley JB, O’Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-88.
- 5. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358.
- 6. Australian Government Department of Health and Ageing. Australian adverse drug reactions bulletin 2006. http://www.tga.gov.au/adr/aadrb.htm (accessed Aug 2006).
- 7. Hunter D. First, gather the data. N Engl J Med 2006; 354: 329-331.
- 8. Strom BL. How the US drug safety system should be changed. JAMA 2006; 295: 2072-2075.
- 9. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-184.
- 10. McEwen J, Purcell PM, Hill RL, et al. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiol Drug Saf 2007; 16: 65-73 [published online ahead of print: 24 Apr 2006]. DOI: 10.1002/pds.1236.
- 11. Australian Government Department of Health and Ageing. Submissions sought on proposed Australia New Zealand Therapeutic Products Authority regulatory scheme. 23 May 2006. http://www.tga.gov.au/tta/consphase1.htm (accessed Sep 2006).
- 12. Platt R, Ommaya A. A beneficial side effect of the Medicare drug benefit. N Engl J Med 2005; 353: 2742-2743.
- 13. Nelson MR, Tonkin AM, Cicuttini FM, McNeil JJ. COX-2 inhibitors: exemplars of the drug-safety conundrum [editorial]. Med J Aust 2005; 182: 262-263. <MJA full text>
- 14. Laupacis A, Paterson M, Mamdani M, et al. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 2003; 169: 1167-1170.
- 15. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719-724.
- 16. Evans JM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Brit J Clin Pharmacol 1999; 47: 105-110.
- 17. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischaemia Research Group; Ischaemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
- 18. Vlahakes GJ. The value of phase 4 clinical testing. N Engl J Med 2006; 354: 413-415.
- 19. PHARMO Institute for Drug Outcomes Research. PHARMO report. Innovations in pharmacotherapy. Utrecht: PHARMO Institute, 2000. http://www.pharmo.net/pdf/reports/Innovations%20in%20Pharmacotherapy .PDF (accessed Dec 2006).
- 20. Ardoin SP, Sundy JS. Update on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 2006; 18: 221-226.
- 21. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
- 22. Brameld KJ, Thomas MA, Holman CD, et al. Validation of linked administrative data on end-stage renal failure: application of record linkage to a “clinical base population”. Aust N Z J Public Health 1999; 23: 464-467.
- 23. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-459.
- 24. Stryer D, Tunis S, Hubbard H, Clancy C. The outcomes of outcomes and effectiveness research: impacts and lessons from the first decade. Health Serv Res 2000; 35: 977-993.
- 25. Chen J, He H, Li J, et al. Representing association classification rules mined from health data. In: Khosla R, Howlett RJ, Jain LC, editors. Knowledge-based intelligent information and engineering. Lecture Notes in Computer Science. Vol. 3683. Berlin: Springer, 2005: 1225-1231.
- 26. Li J, Fu AW, He H, et al. Mining risk patterns in medical data. In: Grossman RL, Bayardo R, Bennett K, Vaidya J, editors. Proceedings of the 11th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; 2005 Aug 21-24; Chicago, Ill. New York: ACM Press, 2005: 770-775.
- 27. The Sax Institute. Centre for Health Record Linkage. http://www.saxinstitute.org.au/researchassetsprograms/BetterHealthServicesThroughResearch/CentreforHealthRecordLinkage.cfm?objid=647 (accessed Jan 2007).
- 28. Kelman CW, Bass AJ, Holman CD. Research use of linked health data — a best practice protocol. Aust N Z J Public Health 2002; 26: 251-255.
- 29. Evans JM, MacDonald TM. Misclassification and selection bias in case–control studies using an automated database. Pharmacoepidemiol Drug Saf 1997; 6: 313-318.
- 30. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Causes Control 2001; 12: 111-115.
- 31. Sorensen HT, Mellemkjaer L, Olsen JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2001; 52: 313-318.
- 32. Australian Government Department of Health and Ageing. National medicines policy 2000. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-objectives-policy.htm/$FILE/nmp2000.pdf (accessed Aug 2006).
- 33. Best Practice Advocacy Centre. Responsible use of pharmaceuticals. Best practice guidelines. 2006. http://www.bpac.org.nz/ (accessed Aug 2006).
- 34. Australian Government Department of Education, Science and Training. National Collaborative Research Infrastructure Strategy (NCRIS). 2005. http://www.dest.gov.au/sectors/research_sector/policies_issues_reviews/key_issues/ncris/default.htm (accessed Aug 2006).
- 35. Prime Minister’s Science, Engineering and Innovation Council (PMSEIC) Working Group. From data to wisdom: pathways to successful data management for Australian science. Working group on data for science report to PMSEIC. Canberra: PMSEIC, Dec 2006. http://www.dest.gov.au/sectors/science_innovation/publications_resources/profiles/Presentation_Data_for_Science.htm (accessed Jan 2007).
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.